GLPGF : Summary for GALAPAGOS NV NPV - Yahoo Finance

U.S. Markets close in 5 hrs 8 mins

Galapagos NV (GLPGF)


Other OTC - Other OTC Delayed Price. Currency in USD
Add to watchlist
64.990.00 (0.00%)
As of 9:42 AM EDT. Market open.
Interactive chart
  • 1d
  • 5d
  • 1m
  • 6m
  • YTD
  • 1y
  • 2y
  • 5y
  • 10y
  • Max
1d
Previous Close64.99
Open0.00
Bid0.00 x
Ask0.00 x
Day's Range0.00 - 0.00
52 Week Range
Volume0
Avg. Volume58
Market Cap2.8B
Beta0.30
PE Ratio (TTM)-55.17
EPS (TTM)N/A
Earnings DateN/A
Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target EstN/A
Trade prices are not sourced from all markets
  • GuruFocus.com9 days ago

    Testing of Treatment for Cystic Fibrosis Patients Begins

    Results of study will be released in the 2nd quarter of 2017

  • Gilead Sciences, Inc. (GILD) Takes Lead Against AbbVie Inc (ABBV) On Crohn’s Disease Treatment
    Insider Monkey9 days ago

    Gilead Sciences, Inc. (GILD) Takes Lead Against AbbVie Inc (ABBV) On Crohn’s Disease Treatment

    Gilead Sciences, Inc. (NASDAQ:GILD) might as well have quashed rumors making waves claiming it is planning to acquire Belgium-based Galapagos NV (ADR) (NASDAQ:GLPG). The drug maker is paying a $50 million milestone payment for the development of Crohn’s drug filgotinib, and that appears to be its main play for the moment. Filgotinib Phase 3 Trial […]

  • Weighing In On Galapagos NV (ADR) (GLPG)’s Lead Studies
    Insider Monkey15 days ago

    Weighing In On Galapagos NV (ADR) (GLPG)’s Lead Studies

    Galapagos NV (ADR) (NASDAQ:GLPG) just updated the markets as to the status of a couple of its lead development programs, and while the company hasn’t really moved on the update, there’s plenty of potential for volatility going forward as the content of the releases plays out. Here’s what’s important. The company is a biotech based […]